2016-12-08| Interviews

An Interview with Dr. Chien-hsiang Tang on Genomics Era: Three Major Biomedical Challenges in Taiwan

by GeneOnline
Share To
The hottest topics of the global biomedical industry include immunotherapy, liquid biopsy, as well as the Next Generation Sequencing Technology (NGS), and companion diagnostics. Many experts and scholars believe that NGS will replace the traditional Sanger sequencing, and become the mainstream of the genetic testing market due to its advantage of high quality and low price. Is it really so? How can Taiwan assemble its domestic resources and promote the excellent R & D capabilities to the global market? It is with a great honor to interview the director of scientific research of Libo Health & Medical Corporation (Libo Health), Dr. Chien-hsiang Tang (唐建翔), who will share his recommendations with us through his own observations of the industry. How should Genetic Testing be going? Just follow the Medical demands.

It's free! Log in now to read

Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
Scroll to Top